Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
The protein encoded by EHMT1 is a histone methyltransferase that is part of the E2F6 complex, which represses transcription. Additionally we are shipping EHMT1 Proteins (4) and EHMT1 Kits (2) and many more products for this protein.
Showing 10 out of 135 products:
GLP (show GOLGA6A Antibodies)/G9a (show EHMT2 Antibodies) H3K9 methyltransferase complex is an enzyme counteracting Jmjd1a (show KDM3A Antibodies)-mediated H3K9 demethylation at the Sry (show SRY Antibodies) locus in gonadal somatic cells
miR (show MLXIP Antibodies)-217-mediated, genetic, or pharmacological inactivation of EHMT1/2 was sufficient to promote pathological hypertrophy
EHMT1 Mediates Homeostatic Synaptic Scaling
The stress-induced Brg1 (show SMARCA4 Antibodies)-G9a (show EHMT2 Antibodies)/GLP (show GOLGA6A Antibodies)-Dnmt3 interactions and sequence of repressive chromatin assembly on Myh6 (show MYH6 Antibodies) promoter illustrates a molecular mechanism by which the heart epigenetically responds to environmental signals.
data provide genetic and pharmacologic evidence that EHMT1 and EHMT2 (show EHMT2 Antibodies) are epigenetic regulators involved in gamma-globin repression and represent a novel therapeutic target for SCD (show SCD Antibodies).
histone methyltransferase activities of GLP (show GOLGA6A Antibodies) and G9a (show EHMT2 Antibodies) are stimulated by neighboring nucleosomes that are premethylated at H3K9
Prdm16 (show PRDM16 Antibodies) was required in young mice to suppress the expression of white-fat-selective genes in BAT (show BAAT Antibodies) through recruitment of the histone methyltransferase Ehmt1.
G9a (show EHMT2 Antibodies) and GLP (show GOLGA6A Antibodies) have an essential role in normal morphogenesis of the atrioventricular septum through regulation of the size of the atrioventricular cushion.
Reduced Euchromatin histone methyltransferase 1 (show DNMT1 Antibodies) causes developmental delay, hypotonia, and cranial abnormalities associated with increased bone gene expression in Kleefstra syndrome mice.
EHMT1 is an essential BAT (show BAAT Antibodies)-enriched lysine methyltransferase in the PRDM16 (show PRDM16 Antibodies) transcriptional complex and controls brown adipose cell fate
trr (show TXNRD1 Antibodies) and G9a (show EHMT2 Antibodies) also have common direct targets, including the Drosophila ortholog of Arc (show NOL3 Antibodies) (Arc1 (show CDH1 Antibodies)), a key regulator of synaptic plasticity. Our data highlight the clinical and molecular convergence between the KMT2 and EHMT protein families, which may contribute to a molecular network underlying a larger group of intellectual disability / autism spectrum disorder -related disorders.
missense variants in EHMT1 that lead to protein misfolding and disrupted histone mark binding can lead to Kleefstra Syndrome [case reports]
we find an estrogen receptor (show ESR1 Antibodies)-independent synthetic lethal interaction between a GATA3 (show GATA3 Antibodies) frameshift mutant with an extended C-terminus and the histone methyltransferases G9A (show EHMT2 Antibodies) and GLP (show RCBTB1 Antibodies), indicating perturbed epigenetic regulation
Selective degradation of the mutant EHMT1 mRNA leads to Kleefstra syndrome.
G9a (show EHMT2 Antibodies) and GLP (show RCBTB1 Antibodies) are required for stable maintenance of imprinted DNA methylation (show HELLS Antibodies) in embryonic stem cells.
the clinical picture we found in Norwegian patients with Kleefstra syndrome is similar to the findings described in the literature. An interesting point is that in the literature >85% of the patients have a deletion of 9q34.3 and the remaining have a mutation in the EHMT1 gene, whereas in this study we found 50% with a deletion, and 50% with a mutation.
Data indicate zinc finger proteins ZNF644 (show ZNF644 Antibodies) and WIZ (show ZNF803 Antibodies) as two core subunits in the histone-lysine N-methyltransferase G9a (show EHMT2 Antibodies)/GLP (show RCBTB1 Antibodies) complex, and interact with the transcription activation domain of G9a (show EHMT2 Antibodies) and GLP (show RCBTB1 Antibodies).
data provide genetic and pharmacologic evidence that EHMT1 and EHMT2 (show EHMT2 Antibodies) are epigenetic regulators involved in gamma-globin (show HBG1 Antibodies) repression and represent a novel therapeutic target for SCD (show SCD Antibodies).
The expression level of EHMT1 and EHMT2 (show EHMT2 Antibodies) inversely correlates with the type I interferon (show IFNA Antibodies) responsiveness in chronic myeloid leukemia (show BCL11A Antibodies) cell lines.
The current knowledge on the mechanisms of action and function of EHMT1, with particular emphasis on their interplay in the regulation of chromatin states and biological processes.
The protein encoded by this gene is a histone methyltransferase that is part of the E2F6 complex, which represses transcription. The encoded protein methylates the Lys-9 position of histone H3, which tags it for transcriptional repression. This protein may be involved in the silencing of MYC- and E2F-responsive genes and therefore could play a role in the G0/G1 cell cycle transition. Defects in this gene are a cause of chromosome 9q subtelomeric deletion syndrome (9q-syndrome). Two transcript variants encoding different isoforms have been found for this gene.
euchromatic histone methyltransferase 1
, histone-lysine N-methyltransferase, H3 lysine-9 specific 5
, euchromatic histone-lysine N-methyltransferase 1
, histone-lysine N-methyltransferase EHMT1
, histone-lysine N-methyltransferase, H3 lysine-9 specific 5-like
, G9a-like protein 1
, lysine N-methyltransferase 1D
, G9a like protein
, H3-K9-HMTase 5
, histone H3-K9 methyltransferase 5